팝업레이어 알림


 

PREV

NEXT

Deciphering (Aging) &
Beyond (Longevity)

We CRAVE longevity with dignity

Novel Insights into MicroRNAs
and Senescence

Innovative Gene therapy
for Neurological Diseases

Business

VIRAL VECTOR CDMO

Viral vector-specific CDMO based on virus production/purification capabilities

Business

Gene Therapy of ANLBIO

Gene therapy for neurodegenerative diseases targeting microRNA and others

Business

AAV Delivery Platform of ANLBIO

gene therapy modalities with an innovative delivery platform of viral vectors including AAV

PIPELINE

Candidate Indication Development status
  • Research
  • Lead Optimization
  • In Vitro
  • In Vivo
  • Phase Ⅰ
  • Phase Ⅱ
  • Phase Ⅲ
  • NDA
  • Commercialization
miR - based Gene Therapy ANL-101 Alzheimer´s Disease
In Vivo

ANL-102 MCI
Lead Optimization

ANL-103 Parkinson´s Disease
Lead Optimization

Monogenic gene therapy ANL-301 Undisclosed
In Vitro

ANL-302 Undisclosed
Lead Optimization

ANL-303 Undisclosed
Research

좌우로 스크롤 하시면 전체 내용을 확인할 수 있습니다.

PARTNER

  • Partner
  • Investment
  • Biovian

  • Premier Research

  • Charles River

  • MedySapiens

  • Temple University Lewis Katz School of Medicine

  • POSCO CAPITAL

  • KyungDong pharm

  • HYUNDAI VENTURE INVESTMENT

  • Friend Investment Partners

  • BNK VENTURE CAPITAL

NOTICE

VIEW MORE

NEWS

VIEW MORE

TOP